Literature DB >> 27780797

Prognostic Value of E-Cadherin and β-Catenin in Triple-Negative Breast Cancer.

Tiansheng Shen1, Kui Zhang2, Gene P Siegal1, Shi Wei1.   

Abstract

OBJECTIVES: To analyze the expression of E-cadherin and β-catenin in triple-negative breast cancer (TNBC) to assess their prognostic significance.
METHODS: The expression of E-cadherin and β-catenin was examined semiquantitatively and correlated with other pathologic factors and survival outcomes.
RESULTS: Of 72 consecutive TNBCs, 56% showed reduced membranous expression of E-cadherin or β-catenin, with a strong correlation to each other. Of the clinicopathologic factors analyzed, tumor size and nodal status were significantly associated with overall survival and disease-specific survival, while the latter remained an independent factor by multivariate analysis. Reduced E-cadherin and β-catenin were both significantly associated with a poor overall survival and disease-specific survival by univariate and multivariate analyses.
CONCLUSIONS: E-cadherin and β-catenin expression provides discriminative prognostic power independent of conventional pathologic factors, thus further reinforcing the important role of cell adhesion molecules in the process of tumor metastasis, especially in TNBC. © American Society for Clinical Pathology, 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  Breast cancer; E-cadherin; Prognosis; Triple negative; β-catenin

Mesh：

Substances：

Year:  2016        PMID： 27780797     DOI： 10.1093/ajcp/aqw183

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


  17 in total

1.  Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression.

Authors:  Bilal Bin Hafeez; Aditya Ganju; Mohammed Sikander; Vivek K Kashyap; Zubair Bin Hafeez; Neeraj Chauhan; Shabnam Malik; Andrew E Massey; Manish K Tripathi; Fathi T Halaweish; Nadeem Zafar; Man M Singh; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

2.  Dickkopf-1 (Dkk1) protein expression in breast cancer with special reference to bone metastases.

Authors:  Mariz Kasoha; Rainer M Bohle; Anita Seibold; Christoph Gerlinger; Ingolf Juhasz-Böss; Erich-Franz Solomayer
Journal:  Clin Exp Metastasis       Date:  2018-09-20       Impact factor: 5.150

3.  First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.

Authors:  Anna Capasso; Stacey M Bagby; Kyrie L Dailey; Naomi Currimjee; Betelehem W Yacob; Anastasia Ionkina; Julie G Frank; Deog Joong Kim; Christina George; Young B Lee; Ely Benaim; Brian Gittleman; Sarah J Hartman; Aik Choon Tan; Jihye Kim; Todd M Pitts; S Gail Eckhardt; John J Tentler; Jennifer R Diamond
Journal:  Mol Cancer Ther       Date:  2019-09-05       Impact factor: 6.261

4.  Regulation of valproic acid induced EMT by AKT/GSK3β/β-catenin signaling pathway in triple negative breast cancer.

Authors:  Zeynep Ozman; Betul Ozbek Iptec; Elvan Sahin; Gamze Guney Eskiler; Asuman Deveci Ozkan; Suleyman Kaleli
Journal:  Mol Biol Rep       Date:  2021-01-30       Impact factor: 2.316

5.  Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling.

Authors:  Xiangzhou Chen; Mingqiang Yang; Jiang Yin; Pan Li; Shanshan Zeng; Guopei Zheng; Zhimin He; Hao Liu; Qian Wang; Fan Zhang; Danyang Chen
Journal:  Cell Commun Signal       Date:  2022-06-17       Impact factor: 7.525

6.  Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.

Authors:  Sarmad Al-Marsoummi; Emilie Vomhof-DeKrey; Marc D Basson
Journal:  Cell Physiol Biochem       Date:  2019

Review 7.  Wnt/beta-catenin pathway: modulating anticancer immune response.

Authors:  Sachin Gopalkrishna Pai; Benedito A Carneiro; Jose Mauricio Mota; Ricardo Costa; Caio Abner Leite; Romualdo Barroso-Sousa; Jason Benjamin Kaplan; Young Kwang Chae; Francis Joseph Giles
Journal:  J Hematol Oncol       Date:  2017-05-05       Impact factor: 17.388

8.  IMP3 Stabilization of WNT5B mRNA Facilitates TAZ Activation in Breast Cancer.

Authors:  Sanjoy Samanta; Santosh Guru; Ameer L Elaimy; John J Amante; Jianhong Ou; Jun Yu; Lihua J Zhu; Arthur M Mercurio
Journal:  Cell Rep       Date:  2018-05-29       Impact factor: 9.423

9.  E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Authors:  Ilirjana Bajrami; Rebecca Marlow; Marieke van de Ven; Rachel Brough; Helen N Pemberton; Jessica Frankum; Feifei Song; Rumana Rafiq; Asha Konde; Dragomir B Krastev; Malini Menon; James Campbell; Aditi Gulati; Rahul Kumar; Stephen J Pettitt; Mark D Gurden; Marta Llorca Cardenosa; Irene Chong; Patrycja Gazinska; Fredrik Wallberg; Elinor J Sawyer; Lesley-Ann Martin; Mitch Dowsett; Spiros Linardopoulos; Rachael Natrajan; Colm J Ryan; Patrick W B Derksen; Jos Jonkers; Andrew N J Tutt; Alan Ashworth; Christopher J Lord
Journal:  Cancer Discov       Date:  2018-04       Impact factor: 39.397

10.  The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.

Authors:  Barbara Adamo; Giuseppina Rosaria Rita Ricciardi; Antonio Ieni; Tindara Franchina; Carmine Fazzari; Maria Vita Sanò; Giuseppe Angelico; Caruso Michele; Giovanni Tuccari; Vincenzo Adamo
Journal:  Oncotarget       Date:  2017-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.